Original Article
Impaired Glucose Transport as a Cause of Decreased Insulin-Stimulated Muscle Glycogen Synthesis in Type 2 Diabetes
N Engl J Med 1999; 341:240-246July 22, 1999
- Abstract
Background
Insulin resistance, a major factor in the pathogenesis of type 2 diabetes mellitus, is due mostly to decreased stimulation of glycogen synthesis in muscle by insulin. The primary rate-controlling step responsible for the decrease in muscle glycogen synthesis is not known, although hexokinase activity and glucose transport have been implicated.
Methods
We used a novel nuclear magnetic resonance approach with carbon-13 and phosphorus-31 to measure intramuscular glucose, glucose-6-phosphate, and glycogen concentrations under hyperglycemic conditions (plasma glucose concentration, approximately 180 mg per deciliter [10 mmol per liter]) and hyperinsulinemic conditions in six patients with type 2 diabetes and seven normal subjects. In vivo microdialysis of muscle tissue was used to determine the gradient between plasma and interstitial-fluid glucose concentrations, and open-flow microperfusion was used to determine the concentrations of insulin in interstitial fluid.
Results
The time course and concentration of insulin in interstitial fluid were similar in the patients with diabetes and the normal subjects. The rates of whole-body glucose metabolism and muscle glycogen synthesis and the glucose-6-phosphate concentrations in muscle were approximately 80 percent lower in the patients with diabetes than in the normal subjects under conditions of matched plasma insulin concentrations. The mean (±SD) intracellular glucose concentration was 2.0±8.2 mg per deciliter (0.11±0.46 mmol per liter) in the normal subjects. In the patients with diabetes, the intracellular glucose concentration was 4.3±4.9 mg per deciliter (0.24±0.27 mmol per liter), a value that was 1/25 of what it would be if hexokinase were the rate-controlling enzyme in glucose metabolism.
Conclusions
Impaired insulin-stimulated glucose transport is responsible for the reduced rate of insulin-stimulated muscle glycogen synthesis in patients with type 2 diabetes mellitus.
Media in This Article
Figure 4
Representative 13C NMR Spectra of Muscle and Plasma during an Infusion of [1-13C]Glucose and [1-13C]Mannitol under Hyperglycemic–Hyperinsulinemic Conditions in a Patient with Type 2 Diabetes.Figure 1
Potential Rate-Controlling Steps in Insulin Stimulation of Glycogen Synthesis in a Muscle Cell.Article Activity
- Article
Diabetes mellitus is the most common metabolic disease in the world.1 Over 90 percent of patients with diabetes have type 2, and although the primary factors that cause this disease are unknown, it is clear that insulin resistance has an important role in its development. Evidence of this role comes from longitudinal studies showing that insulin resistance precedes the onset of the disease by 10 to 20 years,2-4 from cross-sectional studies in which insulin resistance is a consistent finding in patients with type 2 diabetes,5-7 and from prospective studies showing that insulin resistance is the best predictor of the development of diabetes.2-4
Insulin resistance in patients with type 2 diabetes can be attributed mostly to decreased stimulation of muscle glycogen synthesis by insulin,8,9 and defects in glycogen synthase,10-12 hexokinase,13-17 and glucose transport16-19 have all been implicated in the reduced rate of glycogen synthesis (Figure 1Figure 1
Potential Rate-Controlling Steps in Insulin Stimulation of Glycogen Synthesis in a Muscle Cell.). To determine the relative importance of these factors as determinants of the uptake and metabolism of muscle glucose, we used nuclear magnetic resonance (NMR) spectroscopy with carbon-13 and phosphorus-31 (13C–31P NMR) to measure intracellular concentrations of glucose, glucose-6-phosphate, and glycogen in muscle in patients with type 2 diabetes and normal subjects. Because it has been proposed that decreased delivery of insulin to the muscle underlies the insulin resistance in patients with type 2 diabetes,20 we also measured insulin concentrations in interstitial fluid.Methods
Subjects
We performed NMR measurements and hyperglycemic–hyperinsulinemic clamp studies in seven normal subjects (four men and three women; age range, 24 to 77 years) and in six men with type 2 diabetes (age range, 39 to 67 years). The mean (±SD) body-mass index (calculated as the weight in kilograms divided by the square of the height in meters) was 22.3±1.9 in the normal subjects and 30.7±3.7 in the patients with diabetes. The hyperglycemic–hyperinsulinemic clamp studies were performed after the subjects had eaten an isocaloric diet (55 percent carbohydrate, 20 percent protein, and 25 percent fat) for three days and then fasted overnight. In the group of patients with diabetes, the mean duration of the disease was 9±7 years, and the mean value for glycosylated hemoglobin was 11.8±3.1 percent (normal range, 6 to 8 percent); none of the patients had taken any oral hypoglycemic drugs for at least eight days before the study.
We measured insulin concentrations in interstitial fluid by open-flow microperfusion techniques, and we used microdialysis techniques to determine the gradient between plasma and interstitial glucose concentrations during a similar clamp study in five normal subjects (two men and three women; age range, 34 to 67 years; body-mass index, 28.8±7.8) and six patients with type 2 diabetes (five men and one woman; age range, 33 to 69 years; body-mass index, 30.9±5.6). Two of the patients with type 2 diabetes participated in both the NMR studies and the interstitial-fluid studies. The six patients participating in the interstitial-fluid studies had had diabetes for a mean of 11±7 years and had a mean glycosylated hemoglobin value of 11.4±2.8 percent; all six were receiving their usual treatment while these studies were done. None of the patients in any of the studies were being treated with insulin.
The study protocols were reviewed and approved by the Human Investigation Committee of Yale University School of Medicine. All the subjects gave written informed consent.
NMR and Hyperglycemic–Hyperinsulinemic Clamp Studies
Protocol 1
After the subjects had fasted overnight, Teflon catheters were inserted into an antecubital vein in each arm for blood drawing and infusions. The subjects were placed in a 2.1-T NMR spectrometer, and glucose-6-phosphate in the gastrocnemius muscle was measured by 31P NMR spectroscopy. An infusion of somatostatin (0.1 μg per kilogram of body weight per minute) was then started and was continued throughout the study to inhibit endogenous insulin secretion. Five minutes later, insulin was given as a primed continuous infusion (40 mU per square meter of body-surface area per minute) along with a primed continuous infusion of glucose (20 to 40 percent enriched with [1-13C]glucose) for 220 minutes. The latter infusion was periodically adjusted to maintain the plasma glucose concentration at about 180 mg per deciliter (10 mmol per liter) for the duration of the experiment. Blood samples were obtained every 15 minutes from a warmed arm vein for measurements of plasma insulin, glucose, and mannitol and 13C enrichment of glucose and mannitol. The mean rate of glucose infusion, minus the rate of urinary glucose excretion, served as a measure of the rate of whole-body glucose metabolism.
Protocol 2
To determine the relative roles of glucose transport and hexokinase activity in glycogen synthesis in the patients with diabetes, four of the patients were studied again under identical hyperglycemic conditions but with the insulin-infusion rate increased by a factor of 10 (400 mU per square meter per minute).
Protocols 1 and 2
The change in glucose-6-phosphate in response to insulin stimulation was measured between 45 and 60 minutes after the start of the insulin infusion. Thereafter, serial 13C NMR spectra of the muscle were recorded to determine the rate of muscle glycogen synthesis between 90 and 120 minutes after the start of the infusion.9 At 120 minutes, an infusion of mannitol (99 percent enriched with [1-13C]mannitol) was begun, and intracellular glucose was measured between 180 and 220 minutes.21
Glucose and Insulin Concentrations in Interstitial Fluid
After the subjects had fasted overnight, two probes were inserted into the gastrocnemius muscle to obtain samples of interstitial fluid: a microdialysis probe (CMA60, CMA/Microdialysis, Solna, Sweden) for the measurement of interstitial glucose, and an open-flow microperfusion probe for the measurement of interstitial insulin.22 After a three-hour equilibration period, a hyperglycemic–hyperinsulinemic clamp study was performed as described above.
The microdialysis probe was perfused with artificial extracellular fluid (sodium chloride, 135 mmol per liter; potassium chloride, 3 mmol per liter; magnesium chloride, 1 mmol per liter; calcium chloride, 1.2 mmol per liter; ascorbate, 200 μmol per liter; and sodium phosphate buffer, 2 mmol per liter, adjusted to pH 7.4) at a flow rate of 0.3 μl per minute with the use of a portable pump (CMA106, CMA/Microdialysis). At this flow rate, the rate of recovery with the microdialysis probe is almost 100 percent.23 The open-flow microperfusion probe was perfused at a flow rate of 1 μl per minute. The inlet of the double-lumen probe was connected to a bag containing artificial extracellular fluid of the same composition as that used for microdialysis, and the outlet was connected to a peristaltic pump (Minipuls 3, Gilson, Middleton, Wis.). Effluent samples for the measurement of insulin were collected at 10-minute intervals. Although the equilibration between the perfusate and the interstitial fluid is not complete at this flow rate (the effluent concentration is lower than the interstitial concentration), the perfusion flow rates were the same in all studies. Therefore, the dilution of insulin in the effluent was the same for all subjects, and differences in the effluent insulin concentrations reflected differences in the interstitial insulin concentrations.
Analytic Procedures
Glucose in plasma and muscle-tissue effluent was measured by the glucose oxidase method (Glucose Autoanalyzer II, Beckman Instruments, Fullerton, Calif.). Plasma insulin was measured with the use of a double-antibody radioimmunoassay (Diagnostic Systems Laboratories, Webster, Tex.), and interstitial fluid insulin was measured with the use of an ultrasensitive human insulin radioimmunoassay (Linco Research, St. Charles, Mo.). The relative concentrations of plasma [1-13C]glucose and [1-13C]mannitol were determined by 13C NMR spectroscopy, and 13C enrichment of plasma glucose and mannitol was measured by gas chromatography–mass spectrometry.24
Calculations
The rate of muscle glycogen synthesis was determined according to the increase in the amplitude of the signal for carbon 1 in muscle glycogen, with the use of 13C NMR spectroscopy.9 The rate of glycogen synthesis was calculated from the slope of the least-squares linear fit of the glycogen-concentration curve.
Intracellular glucose concentrations and the ratio of the intracellular volume to the extracellular volume were determined by comparing 13C NMR spectra for muscle and plasma concentrations of glucose and mannitol, as described previously.24 The concentration of intracellular glucose was calculated as the difference between total tissue glucose, measured with the use of [1-13C]mannitol as an in vivo internal concentration standard, and the extracellular glucose concentration corrected for the ratio of the volume of the intracellular space to the volume of the extracellular space.24 The extracellular glucose concentration was calculated on the basis of the plasma glucose concentration and the gradient between the plasma and interstitial-fluid glucose concentrations, as determined by microdialysis. The ratio of the volume of the intracellular space to the volume of the extracellular space was determined on the basis of the relative 13C NMR signal intensities for extracellular mannitol and intracellular creatine (creatine plus creatine phosphate).24
The hypothetical intracellular glucose concentration resulting from reduced hexokinase flux with normal glucose-transport kinetics was calculated by simplifying the metabolic steps regulating glycogen-synthesis flux in muscle, as shown in Figure 1. The steady state is represented by the following equation:
Δ[glucosein] / Δt = VGT - V-GT - VHK = 0,
where glucosein is the intracellular glucose concentration, t is time, VGT is the velocity of glucose transport into the cell, V-GT is the velocity of glucose transport out of the cell, and VHK is the velocity of glucose phosphorylation by hexokinase.
Assuming Michaelis–Menten kinetics yields the following equations:
VGT = VGTmax[glucoseex] / (Km1 + [glucoseex])
and
V-GT = V-GTmax[glucosein] / (Km - 1 + [glucosein]),
where VGTmax is the maximal velocity of glucose transport into the cell, glucoseex is the extracellular glucose concentration, Km1 is the Michaelis–Menten constant for glucose transport into the cell, V-GTmax is the maximal velocity of glucose transport out of the cell, and Km - 1 is the Michaelis–Menten constant for glucose transport out of the cell.
We then made the additional assumptions that the transport of glucose by GLUT-4 is the same in both directions (VGTmax = V-GTmax, Km1 = Km - 1) and that the velocity of glucose phosphorylation by hexokinase is approximately equal to the glycogen-synthesis rate in the control subjects (35 mg per liter of muscle per minute [0.20 mmol per liter of muscle per minute]). The use of a Michaelis–Menten constant of 90 mg per deciliter (5 mmol per liter) for GLUT-4,25 with an extracellular glucose concentration of 180 mg per deciliter and an intracellular glucose concentration of 1.8 mg per deciliter (0.1 mmol per liter), resulted in the following calculation of the velocity of glycogen synthesis:
VGTmax[glucoseex] / (Km1 + [glucoseex]) - V-GTmax[glucosein] / (Km - 1 + [glucosein]),
VGTmax[180 / (90 + 180)] - V-GTmax[1.8 / (90+1.8)] = 35 mg per liter of muscle per minute,
and
VGTmax = 54 mg per liter of muscle per minute (0.30 mmol per liter of muscle per minute).
Assuming that the velocity of glucose phosphorylation by hexokinase is decreased in patients with diabetes but not in normal persons and that it is approximately equal to the glycogen-synthesis rate of 4.9 mg per liter of muscle per minute (0.027 mmol per liter of muscle per minute), this calculation can be repeated with a value of 54 mg per liter of muscle per minute for the maximal rate of glucose transport into the cell:
54[180 / (90 + 180)] - 54[[glucosein] / ([glucosein] + 90)] = 4.9 mg per liter of muscle per minute,
and
glucosein = 122 mg per deciliter (6.8 mmol per liter).
Statistical Analysis
Unpaired two-tailed t-tests were used for comparisons between groups. Paired two-tailed t-tests were used to compare the results of the low-dose and high-dose insulin studies in the patients with type 2 diabetes.
Results
Under conditions of a steady-state plasma insulin concentration (approximately 57 μU per milliliter [340 pmol per liter]) and a steady-state plasma glucose concentration (approximately 180 mg per deciliter), which are similar to the postprandial concentrations, the mean (±SD) rate of glucose infusion in the patients with diabetes was approximately 80 percent lower than that in the normal subjects during the NMR measurements (Table 1Table 1
Mean (±SD) Plasma Glucose and Insulin Concentrations and Rate of Glucose Infusion in Normal Subjects and Patients with Type 2 Diabetes during NMR Measurements.). The mean rate of muscle glycogen synthesis and the increment in glucose-6-phosphate concentrations in muscle were also approximately 80 percent lower in the patients with diabetes than in the normal subjects (Figure 2Figure 2
Mean (+SD) Rates of Glycogen Synthesis (Upper Panel) and Incremental Glucose-6-Phosphate (G6P) Concentrations (Lower Panel) in Normal Subjects and Patients with Type 2 Diabetes during Hyperglycemic–Hyperinsulinemic Clamp Studies.), results that are consistent with our previous findings.9,16 The reduction in glucose metabolism and glycogen synthesis could not be attributed to a reduced rate of insulin delivery to the muscle, because the interstitial-fluid insulin concentrations during the hyperglycemic–hyperinsulinemic clamp studies were similar in the patients with diabetes and the normal subjects (Figure 3Figure 3
Mean (±SD) Insulin Concentrations in Plasma and Interstitial Fluid (Open-Flow Microperfusion Effluent) in Muscle over Time in Normal Subjects and Patients with Type 2 Diabetes during Hyperglycemic–Hyperinsulinemic Clamp Studies.).On the basis of a qualitative comparison of the 13C NMR spectra of muscle and plasma during the infusion period (Figure 4Figure 4
Representative 13C NMR Spectra of Muscle and Plasma during an Infusion of [1-13C]Glucose and [1-13C]Mannitol under Hyperglycemic–Hyperinsulinemic Conditions in a Patient with Type 2 Diabetes.), the relative concentrations of glucose and mannitol in the total tissue space were similar to those in the plasma space. Since the mannitol signal in muscle arises only from the extracellular space, any intracellular glucose will contribute to an increase in the ratio of the glucose signal to the mannitol signal as compared with this ratio in plasma. The in vivo glucose-to-mannitol ratio is proportional to the ratio of intracellular to extracellular glucose concentrations weighted by the distribution volumes. On the basis of the 13C NMR–measured ratio of mannitol to creatine, the ratio of the volume of intracellular space to the volume of extracellular space was the same in the normal subjects and the patients with diabetes (8±1). Using microdialysis, we found no gradient between the arterialized plasma glucose concentration and the interstitial-fluid glucose concentration (ratio of plasma glucose to interstitial-fluid glucose in the normal subjects, 1.02± 0.02; ratio in the patients with diabetes, 1.01±0.07). Thus, in muscle, glucose is confined almost exclusively to the extracellular space. The intracellular glucose concentration was calculated to be 2.0±8.2 mg per deciliter (0.11±0.46 mmol per liter) in the normal subjects. In the patients with diabetes, the concentration was 4.3±4.9 mg per deciliter (0.24±0.27 mmol per liter), a value that was 1/25 what it would be if hexokinase were the primary rate-controlling enzyme for glycogen synthesis.When the insulin-infusion rate was increased by a factor of 10 in the patients with diabetes, the rates of whole-body glucose metabolism and glycogen synthesis increased by a factor of approximately 4, over the results with a low-dose insulin infusion (Table 1 and Figure 2). These changes were accompanied by an increase in glucose-6-phosphate by a factor of approximately 2 (Figure 2) and a slight decrease in the intracellular glucose concentration, to a measured value of –2.2±5.8 mg per deciliter (–0.12±0.32 mmol per liter, P=0.05). The negative value reflects the imprecision of the measurement of the intracellular glucose concentration when it is less than 5.0 mg per deciliter (0.3 mmol per liter).
Discussion
Intracellular glucose-6-phosphate is an intermediary between glucose transport and glycogen synthesis, and its intracellular concentration is responsive to the relative activities of these two processes. If the activity of glycogen synthase is decreased in patients with diabetes, glucose-6-phosphate will be higher in such patients than in normal subjects. The blunted incremental changes in glucose-6-phosphate in patients with type 2 diabetes in response to insulin stimulation can therefore be ascribed to either decreased glucose-transport activity or decreased hexokinase activity and are consistent with our previous results.16
In the same manner, intracellular glucose is an intermediary between glucose transport and hexokinase activity, and its concentration is responsive to the relative activities of these two processes. To distinguish between impaired glucose transport and impaired hexokinase activity in the patients with diabetes, we measured intracellular glucose using a 13C NMR technique. Unlike the biopsy method, this approach is noninvasive and is not subject to the errors caused by contamination of biopsy tissue with plasma glucose or incomplete removal of nonmuscle constituents. If hexokinase activity were reduced relative to glucose transport in patients with diabetes, one would predict a substantial increase in intracellular glucose. In keeping with this prediction, we recently observed that intracellular glucose is increased in transgenic mice that overexpress the GLUT-1 glucose transporter in skeletal muscle.26 In contrast, if glucose transport is primarily responsible for maintaining intracellular glucose metabolism, intracellular glucose and glucose-6-phosphate should change proportionately. In a recent study in which we used the same NMR approach with 13C and 31P as in this study, insulin resistance in skeletal muscle induced by increasing the plasma free-fatty-acid concentration was associated with a concomitant fall in both glucose-6-phosphate and intracellular glucose, a finding indicative of control at the level of glucose transport.27 The patients with diabetes in our current study did not have a marked accumulation of intracellular glucose in association with a substantially lower rate of glycogen synthesis.
When the rates of muscle glycogen synthesis in four of the patients with diabetes were increased by increasing the insulin-infusion rate by a factor of 10, the changes in the concentrations of intracellular glucose and glucose-6-phosphate (Figure 2) indicated that the rates of glucose transport were matched by increases in the rates of glucose phosphorylation and glycogen synthesis. These data support the hypothesis that glucose-transport activity has a predominant role in insulin-stimulated muscle glycogen synthesis in patients with diabetes,28 but they do not rule out the possibility of additional abnormalities in the glycogen-synthesis pathway, which under these conditions would not have a strong rate-controlling effect. In our study in which free-fatty-acid–induced insulin resistance resulted in decreased glucose-transport activity,27 insulin-stimulated phosphatidylinositol-3-kinase activity was also decreased, and this decrease, in turn, could lead to other defects in the action of insulin. This mechanism would also be consistent with the data in the present study.
A triple-tracer, forearm-infusion technique, combined with a multicompartmental model, has been used in an attempt to distinguish the rate of muscle glucose transport from that of hexokinase activity.17,29 Using an alternative approach with dynamic imaging of [18F]2-deoxyglucose uptake and positron-emission tomography, Kelley et al. found that in patients with type 2 diabetes, unlike normal subjects, there was no stimulation of glucose transport by insulin, and at the same time, there was a blunted increase in glucose phosphorylation.13 These other studies have suggested that the patients had a resistance to the actions of insulin in stimulating both glucose transport and glucose phosphorylation. The inherent assumptions and particular model chosen to interpret the kinetic data in these other studies leave in question the relative importance of glucose transport and glucose phosphorylation in causing insulin resistance in patients with type 2 diabetes.
It has also been hypothesized that decreased delivery of substrate or insulin to the tissue bed might be responsible for insulin resistance in type 2 diabetes.20 In regard to substrate delivery, we found no difference in the 13C NMR–measured ratio of the volume of intracellular space to the volume of extracellular space in the normal subjects and the patients with diabetes, suggesting that there was no substantial difference in insulin-mediated vasodilatation between the two groups. We also found no difference in the interstitial-fluid insulin concentrations during the hyperinsulinemic clamp studies in the two groups, suggesting that the delivery of insulin is not responsible for insulin resistance in patients with type 2 diabetes. This result is consistent with previous studies that found similar time courses for insulin-receptor autophosphorylation in normal subjects and patients with type 2 diabetes.30
Overall, the results of our study are consistent with the hypothesis that glucose transport is the rate-controlling step in insulin-stimulated muscle glycogen synthesis in patients with type 2 diabetes.
Supported by grants from the Public Health Service (RO1 DK-49230, P30 DK-45735, and MO1 RR-00125), and by a grant from the Max–Kade Foundation (to Dr. Trajanoski).
Source Information
From the Departments of Internal Medicine (G.W.C., K.F.P., M.K., J.S., R.S.H., Z.T., S.I., A.D., G.I.S.) and Diagnostic Radiology (D.L.R.) and the Howard Hughes Medical Institute (G.I.S), Yale University School of Medicine, New Haven, Conn.
Address reprint requests to Dr. Shulman at the Howard Hughes Medical Institute, Yale University School of Medicine, Boyer Center for Molecular Medicine, Department of Internal Medicine, P.O. Box 9812, New Haven, CT 06536-8012, or at gerald.shulman@yale.edu.
- References
References
1
National Diabetes Data Group. Diabetes in America. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, 1995. (NIH publication no. 95-1468.)
2
Warram JH ,Martin BC ,Krolewski AS ,Soeldner JS ,Kahn CR . Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909-915
Web of Science | Medline3
Lillioja S ,Mott DM ,Howard BV , et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988;318:1217-1225
Full Text | Web of Science | Medline4
Haffner SM ,Stern MP ,Dunn J ,Mobley M ,Blackwell J ,Bergman RN . Diminished insulin sensitivity and increased insulin response in nonobese, nondiabetic Mexican Americans. Metabolism 1990;39:842-847
CrossRef | Web of Science | Medline5
Reaven GM ,Bernstein R ,Davis B ,Olefsky JM . Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976;60:80-88
CrossRef | Web of Science | Medline6
DeFronzo RA . Lilly Lecture 1987: the triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667-687
Web of Science | Medline7
Cahill GF Jr . Beta-cell deficiency, insulin resistance, or both? N Engl J Med 1988;318:1268-1270
Full Text | Web of Science | Medline8
Lillioja S ,Mott DM ,Zawadzki JK ,Young AA ,Abbott WG ,Bogardus C . Glucose storage is a major determinant of in vivo “insulin resistance“ in subjects with normal glucose tolerance. J Clin Endocrinol Metab 1986;62:922-927
CrossRef | Web of Science | Medline9
Shulman GI ,Rothman DL ,Jue T ,Stein P ,DeFronzo RA ,Shulman RG . Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990;322:223-228
Full Text | Web of Science | Medline10
Bogardus C ,Lillioja S ,Stone K ,Mott D . Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 1984;73:1185-1190
CrossRef | Web of Science | Medline11
Damsbo P ,Vaag A ,Hother-Nielsen O ,Beck-Nielsen H . Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991;34:239-245
CrossRef | Web of Science | Medline12
Wright KS ,Beck-Nielsen H ,Kolterman OG ,Mandarino LJ . Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM. Diabetes 1988;37:436-440
CrossRef | Web of Science | Medline13
Kelley DE ,Mintun MA ,Watkins SC , et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996;97:2705-2713
CrossRef | Web of Science | Medline14
Braithwaite SS ,Palazuk B ,Colca JR ,Edwards CW III ,Hofmann C . Reduced expression of hexokinase II in insulin-resistant diabetes. Diabetes 1995;44:43-48
CrossRef | Web of Science | Medline15
Kruszynska YT ,Mulford MI ,Baloga J ,Yu JG ,Olefsky JM . Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 1998;47:1107-1113
CrossRef | Web of Science | Medline16
Rothman DL ,Shulman RG ,Shulman GI . 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate: evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 1992;89:1069-1075
CrossRef | Web of Science | Medline17
Bonadonna RC ,Del Prato S ,Bonora E , et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 1996;45:915-925
CrossRef | Web of Science | Medline18
Zierath JR ,He L ,Guma A ,Odegoard Wahlstrom E ,Klip A ,Wallberg-Henriksson H . Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 1996;39:1180-1189
CrossRef | Web of Science | Medline19
Dohm GL ,Tapscott EB ,Pories WJ , et al. An in vitro human muscle preparation suitable for metabolic studies: decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest 1988;82:486-494
CrossRef | Web of Science | Medline20
Yang YJ ,Hope ID ,Ader M ,Bergman RN . Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 1989;84:1620-1628
CrossRef | Web of Science | Medline21
Shen J . Use of amplitude and frequency transformations to generate adiabatic pulses of wide bandwidth and low RF power deposition. J Magn Reson B 1996;112:131-140
CrossRef | Medline22
Trajanoski Z ,Brunner GA ,Schaupp L , et al. Open-flow microperfusion of subcutaneous adipose tissue for on-line continuous ex vivo measurement of glucose concentration. Diabetes Care 1997;20:1114-1121
CrossRef | Web of Science | Medline23
Moberg E ,Hagstrom-Toft E ,Arner P ,Bolinder J . Protracted glucose fall in subcutaneous adipose tissue and skeletal muscle compared with blood during insulin-induced hypoglycaemia. Diabetologia 1997;40:1320-1326
CrossRef | Web of Science | Medline24
Cline GW ,Jucker BM ,Trajanoski Z ,Rennings AJ ,Shulman GI . A novel 13C NMR method to assess intracellular glucose concentration in muscle in vivo. Am J Physiol 1998;274:E381-E389
Web of Science | Medline25
Kasanicki MA ,Pilch PF . Regulation of glucose-transporter function. Diabetes Care 1990;13:219-227
CrossRef | Web of Science | Medline26
Cline GW ,Ren J ,Cadman KS ,Marshall B . Redistribution of rate control for insulin stimulated muscle glycogen synthesis in Glut1 transgenic mice. Diabetes 1999;48:Suppl 1:A273-A273 abstract.
Web of Science27
Dresner A ,Laurent D ,Marcucci M , et al. Effect of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103:253-259
CrossRef | Web of Science | Medline28
Shulman RG ,Bloch G ,Rothman DL . In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Proc Natl Acad Sci U S A 1995;92:8535-8542
CrossRef | Web of Science | Medline29
Saccomani MP ,Bonadonna RC ,Bier DM ,DeFronzo RA ,Cobelli C . A model to measure insulin effects on glucose transport and phosphorylation in muscle: a three-tracer study. Am J Physiol 1996;270:E170-E185
Web of Science | Medline30
Nolan JJ ,Ludvik B ,Baloga J ,Reichart D ,Olefsky JM . Mechanisms of the kinetic defect in insulin action in obesity and NIDDM. Diabetes 1997;46:994-1000
CrossRef | Web of Science | Medline
- Citing Articles (109)
Citing Articles
1
Julia Szendroedi, Esther Phielix, Michael Roden. (2011) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nature Reviews Endocrinology
CrossRef2
Donal J. O'Gorman, Anna Krook. (2011) Exercise and the Treatment of Diabetes and Obesity. Medical Clinics of North America 95:5, 953-969
CrossRef3
Julia Szendroedi, Esther Phielix, Michael Roden. 2011. Assessment of Insulin Sensitivity. , 88-105.
CrossRef4
Anna Ciechanowska, Jan M. Wojcicki, Iwona Maruniak-Chudek, Piotr Ladyzynski, Janusz Krzymien. 2011. Microdialysis as a Monitoring System for Human Diabetes. , 359-401.
CrossRef5
U. Kampmann, P. Hoeyem, A. Mengel, O. Schmitz, J. Rungby, L. Orskov, N. Møller. (2011) Insulin dose-response studies in severely insulin-resistant type 2 diabetes-evidence for effectiveness of very high insulin doses. Diabetes, Obesity and Metabolism 13:6, 511-516
CrossRef6
Amanda E. Brandon, Andrew J. Hoy, Lauren E. Wright, Nigel Turner, Bronwyn D. Hegarty, Tristan J. Iseli, X. Julia Xu, Gregory J. Cooney, Asish K. Saha, Neil B. Ruderman, Edward W. Kraegen. (2011) The evolution of insulin resistance in muscle of the glucose infused rat. Archives of Biochemistry and Biophysics 509:2, 133-141
CrossRef7
Sha Jin, Jithesh V. Veetil, Jared R. Garrett, Kaiming Ye. (2011) Construction of a panel of glucose indicator proteins for continuous glucose monitoring. Biosensors and Bioelectronics 26:8, 3427-3431
CrossRef8
Florensia Nailufar, Olivia Mayasari Tandrasasmita, Raymond Rubianto Tjandrawinata. (2011) DLBS3233 increases glucose uptake by mediating upregulation of PPARγ and PPARδ expression. Biomedicine & Preventive Nutrition 1:2, 71-78
CrossRef9
M. Kacerovsky, A. Brehm, M. Chmelik, A. I. Schmid, J. Szendroedi, G. Kacerovsky-Bielesz, P. Nowotny, A. Lettner, M. Wolzt, J. G. Jones, M. Roden. (2011) Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. Journal of Internal Medicine 269:2, 189-199
CrossRef10
Marinette Graaf, Jacco H. Haan, Paul Smits, Alexandra H. Mulder, Arend Heerschap, Cees J. Tack. (2011) The effect of acute exercise on glycogen synthesis rate in obese subjects studied by 13C MRS. European Journal of Applied Physiology 111:2, 275-283
CrossRef11
Makoto MIYAZAKI, Toshiki FUJII, Nobuhiro TAKEDA, Hiroaki MAGOTANI, Kazunori IWANAGA, Masawo KAKEMI. (2011) Chronopharmacological Assessment Identified GLUT4 as a Factor Responsible for the Circadian Variation of the Hypoglycemic Effect of Tolbutamide in Rats. Drug Metabolism and Pharmacokinetics 26:5, 503-515
CrossRef12
Xiao Ma, Tatsuro Egawa, Hajime Kimura, Kouhei Karaike, Shinya Masuda, Nobumasa Iwanaka, Tatsuya Hayashi. (2010) Berberine-induced activation of 5′-adenosine monophosphate–activated protein kinase and glucose transport in rat skeletal muscles. Metabolism 59:11, 1619-1627
CrossRef13
Lina Yang, Zhiyu Qian, Hui Ji, Ruhui Yang, Yuhuan Wang, Liang Xi, Liang Sheng, Bohua Zhao, Xiaoming Zhang. (2010) Inhibitory effect on protein kinase Cθ by Crocetin attenuates palmitate-induced insulin insensitivity in 3T3-L1 adipocytes. European Journal of Pharmacology 642:1-3, 47-55
CrossRef14
François R. Jornayvaz, Varman T. Samuel, Gerald I. Shulman. (2010) The Role of Muscle Insulin Resistance in the Pathogenesis of Atherogenic Dyslipidemia and Nonalcoholic Fatty Liver Disease Associated with the Metabolic Syndrome. Annual Review of Nutrition 30:1, 273-290
CrossRef15
XY Guo. (2010) Antidiabetic effects of Tangnaikang on obese Zucker rats and the mechanism. Journal of Chinese Integrative Medicine 8:6, 535-540
CrossRef16
Derek M Erion, Gerald I Shulman. (2010) Diacylglycerol-mediated insulin resistance. Nature Medicine 16:4, 400-402
CrossRef17
Liang-Cai Zhao, Xiao-Dong Zhang, Shi-Xian Liao, Hong-Chang Gao, He-Yao Wang, Dong-Hai Lin. (2010) A Metabonomic Comparison of Urinary Changes in Zucker and GK Rats. Journal of Biomedicine and Biotechnology 2010, 1-6
CrossRef18
Wolfram Doehner, David Gathercole, Mariantonietta Cicoira, Andreas Krack, Andrew J.S. Coats, Paolo G. Camici, Stefan D. Anker. (2010) Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. International Journal of Cardiology 138:1, 19-24
CrossRef19
Muhammad A. Abdul-Ghani, Ralph A. DeFronzo. (2010) Pathogenesis of Insulin Resistance in Skeletal Muscle. Journal of Biomedicine and Biotechnology 2010, 1-20
CrossRef20
Stephen O’Rahilly. (2009) Human genetics illuminates the paths to metabolic disease. Nature 462:7271, 307-314
CrossRef21
Tatsuro Egawa, Taku Hamada, Naoko Kameda, Kouhei Karaike, Xiao Ma, Shinya Masuda, Nobumasa Iwanaka, Tatsuya Hayashi. (2009) Caffeine acutely activates 5′adenosine monophosphate–activated protein kinase and increases insulin-independent glucose transport in rat skeletal muscles. Metabolism 58:11, 1609-1617
CrossRef22
Chris Boesch. 2009. Human Muscle Studies by Magnetic Resonance Spectroscopy. .
CrossRef23
Jason M Ng, David E Kelley, Bret H Goodpaster. (2009) Mechanisms of insulin resistance assessed by dynamic in-vivo positron emission tomography imaging. Current Opinion in Clinical Nutrition and Metabolic Care 12:5, 508-512
CrossRef24
Z. Szabo, R. G. G. Andersson, H. J. Arnqvist. (2009) Intraoperative muscle and fat metabolism in diabetic patients during coronary artery bypass grafting surgery: a parallel microdialysis and organ balance study. British Journal of Anaesthesia 103:2, 166-172
CrossRef25
Prasanth N. Surampudi, Jennifer John-Kalarickal, Vivian A. Fonseca. (2009) Emerging Concepts in the Pathophysiology of Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, 216-226
CrossRef26
Mina Kim, Joseph Gillen, Bennett A. Landman, Jinyuan Zhou, Peter C.M. van Zijl. (2009) Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments. Magnetic Resonance in Medicine 61:6, 1441-1450
CrossRef27
Nina F. Schwenzer, Petros Martirosian, Jürgen Machann, Christina Schraml, Günter Steidle, Claus D. Claussen, Fritz Schick. (2009) Aging effects on human calf muscle properties assessed by MRI at 3 Tesla. Journal of Magnetic Resonance Imaging 29:6, 1346-1354
CrossRef28
X. F. Gao, W. Chen, X. P. Kong, A. M. Xu, Z. G. Wang, G. Sweeney, D. Wu. (2009) Enhanced susceptibility of Cpt1c knockout mice to glucose intolerance induced by a high-fat diet involves elevated hepatic gluconeogenesis and decreased skeletal muscle glucose uptake. Diabetologia 52:5, 912-920
CrossRef29
Oscar Moreno-Pérez, Antonio Miguel Picó Alfonso, Joaquín Portilla. (2009) Hipogonadismo, disfunción eréctil y disfunción endotelial en varones con infección por el virus de la inmunodeficiencia humana. Medicina Clínica 132:8, 311-321
CrossRef30
P. Erasto, M. van de Venter, S. Roux, D.S. Grierson, A.J. Afolayan. (2009) Effect of leaf extracts of Vernonia amygdalina on glucose utilization in chang-liver, C 2 C 12 muscle and 3T3-L1 cells. Pharmaceutical Biology 47:2, 175-181
CrossRef31
X. Lopez, C. Bouché, E. Tatro, A. B. Goldfine. (2009) Family history of diabetes impacts on interactions between minimal model estimates of insulin sensitivity and glucose effectiveness. Diabetes, Obesity and Metabolism 11:2, 123-130
CrossRef32
Donal J. O'Gorman, Anna Krook. (2008) Exercise and the Treatment of Diabetes and Obesity. Endocrinology & Metabolism Clinics of North America 37:4, 887-903
CrossRef33
Heidi Kuoppamaa, Paulina Skrobuk, Maarit Sihvo, Anne Hiukka, Alexander V. Chibalin, Juleen R. Zierath, Heikki A. Koistinen. (2008) Globular adiponectin stimulates glucose transport in type 2 diabetic muscle. Diabetes/Metabolism Research and Reviews 24:7, 554-562
CrossRef34
Jared R. Garrett, Xinxin Wu, Sha Jin, Kaiming Ye. (2008) pH-insensitive glucose indicators. Biotechnology Progress 24:5, 1085-1089
CrossRef35
Y. Bi, W. P. Sun, X. Chen, M. Li, H. Liang, M. Y. Cai, Y. H. Zhu, X. Y. He, F. Xu, J. P. Weng. (2008) Effect of early insulin therapy on nuclear factor κB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats. Acta Diabetologica 45:3, 167-178
CrossRef36
Danielle Lann, Derek LeRoith. (2007) Insulin Resistance as the Underlying Cause for the Metabolic Syndrome. Medical Clinics of North America 91:6, 1063-1077
CrossRef37
T. P. J. Solomon, A. K. Blannin. (2007) Effects of short-term cinnamon ingestion on in vivo glucose tolerance. Diabetes, Obesity and Metabolism 9:6, 895-901
CrossRef38
Jongsoon Lee, Myung-Sunny Kim. (2007) The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Research and Clinical Practice 77:3, S49-S57
CrossRef39
Peter Holland-Fischer, Per Heden Andersen, Sten Lund, Steen Bønnelykke Pedersen, Lars Vinter-Jensen, Michael F. Nielsen, Andreas Kaal, Rolf Dall, Ole Schmitz, Hendrik Vilstrup. (2007) Muscle GLUT4 in cirrhosis. Journal of Hepatology 47:2, 212-219
CrossRef40
Håkan K. R. Karlsson, Juleen R. Zierath. (2007) Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochemistry and Biophysics 48:2-3, 103-113
CrossRef41
P. C. M. van Zijl, C. K. Jones, J. Ren, C. R. Malloy, A. D. Sherry. (2007) MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proceedings of the National Academy of Sciences 104:11, 4359-4364
CrossRef42
Torben Østergård, Niels Jessen, Ole Schmitz, Lawrence J. Mandarino. (2007) The effect of exercise, training, and inactivity on insulin sensitivity in diabetics and their relatives: what is new?. Applied Physiology, Nutrition, and Metabolism 32:3, 541-548
CrossRef43
Chris Boesch. (2007) Musculoskeletal spectroscopy. Journal of Magnetic Resonance Imaging 25:2, 321-338
CrossRef44
Graeme F. Mason, Kitt Falk Petersen, Robin A. de Graaf, Gerald I. Shulman, Douglas L. Rothman. (2007) Measurements of the anaplerotic rate in the human cerebral cortex using 13 C magnetic resonance spectroscopy and [1- 13 C] and [2- 13 C] glucose. Journal of Neurochemistry 100:1, 73-86
CrossRef45
Giorgio Sesti. (2006) Pathophysiology of insulin resistance. Best Practice & Research Clinical Endocrinology & Metabolism 20:4, 665-679
CrossRef46
D. J. O’Gorman, H. K. R. Karlsson, S. McQuaid, O. Yousif, Y. Rahman, D. Gasparro, S. Glund, A. V. Chibalin, J. R. Zierath, J. J. Nolan. (2006) Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia 49:12, 2983-2992
CrossRef47
S Freeman, J B Bartlett, G Convey, I Hardern, J L Teague, S J G Loxham, J M Allen, S M Poucher, A D Charles. (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. British Journal of Pharmacology 149:6, 775-785
CrossRef48
Chris Boesch, Juergen Machann, Peter Vermathen, Fritz Schick. (2006) Role of proton MR for the study of muscle lipid metabolism. NMR in Biomedicine 19:7, 968-988
CrossRef49
Britton Chance, Joohee Im, Shoko Nioka, Martin Kushmerick. (2006) Skeletal muscle energetics with PNMR: personal views and historic perspectives. NMR in Biomedicine 19:7, 904-926
CrossRef50
Dominic S. Ng. 2006. Insulin Resistance, Diabetes and its Complications. .
CrossRef51
C. Rattarasarn. (2006) Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes. Acta Physiologica 186:2, 87-101
CrossRef52
Kitt Falk Petersen, Gerald I. Shulman. (2006) New Insights into the Pathogenesis of Insulin Resistance in Humans Using Magnetic Resonance Spectroscopy. Obesity 14:2S, 34S-40S
CrossRef53
Mark D. Turner, Paul G. Cassell, Graham A. Hitman. (2005) Calpain-10: from genome search to function. Diabetes/Metabolism Research and Reviews 21:6, 505-514
CrossRef54
M. Krebs, M. Roden. (2005) Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes, Obesity and Metabolism 7:6, 621-632
CrossRef55
Rebecca Parish, Kitt Falk Petersen. (2005) Mitochondrial dysfunction and type 2 diabetes. Current Diabetes Reports 5:3, 177-183
CrossRef56
L. Al-Khalili, M. Forsgren, K. Kannisto, J. R. Zierath, F. Lönnqvist, A. Krook. (2005) Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia 48:6, 1173-1179
CrossRef57
L.J. Logie, A.E. Brown, S.J. Yeaman, M. Walker. (2005) Calpain inhibition and insulin action in cultured human muscle cells. Molecular Genetics and Metabolism 85:1, 54-60
CrossRef58
J LEAHY. (2005) Pathogenesis of Type 2 Diabetes Mellitus. Archives of Medical Research 36:3, 197-209
CrossRef59
Roger Mcintyre, Jakub Konarski, Virginia Misener, Sidney Kennedy. (2005) Bipolar Disorder and Diabetes Mellitus: Epidemiology, Etiology, and Treatment Implications. Annals of Clinical Psychiatry 17:2, 83-93
CrossRef60
Philippe Gual, Yannick Le Marchand-Brustel, Jean-François Tanti. (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:1, 99-109
CrossRef61
Justin B. Lundbye, Paul D. Thompson. (2005) Statin use in the metabolic syndrome. Current Atherosclerosis Reports 7:1, 17-21
CrossRef62
G. D. Tan, B. A. Fielding, J. M. Currie, S. M. Humphreys, M. D
sage, K. N. Frayn, M. Laville, H. Vidal, F. Karpe. (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:1, 83-95
CrossRef63
Kitt F. Petersen, Sylvie Dufour, Gerald I. Shulman. (2005) Decreased Insulin-Stimulated ATP Synthesis and Phosphate Transport in Muscle of Insulin-Resistant Offspring of Type 2 Diabetic Parents. PLoS Medicine 2:9, e233
CrossRef64
Nigel J. Pearce, Jonathan R.S. Arch, John C. Clapham, Matthew P. Coghlan, Stacey L. Corcoran, Carolyn A. Lister, Andrea Llano, Gary B. Moore, Gregory J. Murphy, Stephen A. Smith, Colleen M. Taylor, John W. Yates, Alastair D. Morrison, Alexander J. Harper, Lynne Roxbee-Cox, Alejandro Abuin, Ed Wargent, Julie C. Holder. (2004) Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter. Metabolism 53:10, 1322-1330
CrossRef65
Jason K. Kim, Jonathan J. Fillmore, Mary Jean Sunshine, Bjoern Albrecht, Takamasa Higashimori, Dong-Wook Kim, Zhen-Xiang Liu, Timothy J. Soos, Gary W. Cline, William R. O’Brien, Dan R. Littman, Gerald I. Shulman. (2004) PKC-θ knockout mice are protected from fat-induced insulin resistance. Journal of Clinical Investigation 114:6, 823-827
CrossRef66
Ralph A DeFronzo. (2004) Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America 88:4, 787-835
CrossRef67
Jason K. Kim, Ruth E. Gimeno, Takamasa Higashimori, Hyo-Jeong Kim, Hyejeong Choi, Sandhya Punreddy, Robin L. Mozell, Guo Tan, Alain Stricker-Krongrad, David J. Hirsch, Jonathan J. Fillmore, Zhen-Xiang Liu, Jianying Dong, Gary Cline, Andreas Stahl, Harvey F. Lodish, Gerald I. Shulman. (2004) Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. Journal of Clinical Investigation 113:5, 756-763
CrossRef68
Naresh Kumar, Chaman L Kaul, Ansurudeen Ishrath, Chinmoy S Dey. (2004) Combination of metformin and thiazolidindiones restore insulin signalling in insulin-resistant cultured myotubes. Life Sciences 74:15, 1877-1888
CrossRef69
Jacco H. de Haan, D.W.J. Klomp, C.J. Tack, A. Heerschap. (2003) Optimized detection of changes in glucose-6-phosphate levels in human skeletal muscle by31P MR spectroscopy. Magnetic Resonance in Medicine 50:6, 1302-1306
CrossRef70
Ralph A. DeFronzo, Lawrence Mandarino, Eleuterio Ferrannini. 2003. Metabolic and Molecular Pathogenesis of Type 2 Diabetes Mellitus. .
CrossRef71
Peter Vollenweider. (2003) Insulin Resistant States and Insulin Signaling. Clinical Chemistry and Laboratory Medicine 41:9, 1107-1119
CrossRef72
Marek H. Dominiczak. (2003) Obesity, Glucose Intolerance and Diabetes and Their Links to Cardiovascular Disease. Implications for Laboratory Medicine. Clinical Chemistry and Laboratory Medicine 41:9, 1266-1278
CrossRef73
Guenther Boden, Peter Cheung, Maria Mozzoli, Susan K Fried. (2003) Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52:6, 753-759
CrossRef74
Kathleen L. Wyne, David S.H. Bell, Seth Braunstein, Andrew J. Drexler, Jeffrey L. Miller, James G. Nuckolls. (2003) Trends in Management of Type 2 Diabetes. The Endocrinologist 13:Sup 1, S1-S21
CrossRef75
Dinesh Jagasia, Patrick H. McNulty. (2003) Diabetes Mellitus and Heart Failure. Congestive Heart Failure 9:3, 133-141
CrossRef76
Tadahiro Kitamura, C. Ronald Kahn, Domenico Accili. (2003) I
NSULIN RECEPTOR KNOCKOUT MICE . Annual Review of Physiology 65:1, 313-332
CrossRef77
H. Herkner, N. Klein, C. Joukhadar, E. Lackner, H. Langenberger, M. Frossard, C. Bieglmayer, O. Wagner, M. Roden, M. Muller. (2003) Transcapillary insulin transfer in human skeletal muscle. European Journal of Clinical Investigation 33:2, 141-146
CrossRef78
G. Boden, G. I. Shulman. (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. European Journal of Clinical Investigation 32:s3, 14-23
CrossRef79
N. A. Lee, M. Matsuda, P. Bressler, T. Pratipanawatr, L. Glass, L. J. Mandarino, R. A. DeFronzo. (2002) Effect of misoprostol (PGE1) on glucose metabolism in type-2-diabetic and control subjects. Diabetes, Obesity and Metabolism 4:3, 195-200
CrossRef80
David Lasky, Enrique Becerra, William Boto, Michele Otim, James Ntambi. (2002) Obesity and gender differences in the risk of type 2 diabetes mellitus in Uganda. Nutrition 18:5, 417-421
CrossRef81
Haruhiko Murata, Paul W. Hruz, Mike Mueckler. (2002) Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16:6, 859-863
CrossRef82
Vitomir Rankovic, D. Micic, Vladimir Bumbasirevic, I. Palibrk, Marica Basic, V. Bukumirovic. (2002) Anestezija kod bolesnika sa diabetes mellitusom. Acta chirurgica iugoslavica 49:1, 47-55
CrossRef83
JÓZSEF TÖZSÉR. (2001) HIV Inhibitors: Problems and Reality. Annals of the New York Academy of Sciences 946:1, 145-159
CrossRef84
Antonio Piñero-Piloña, Philip Raskin. (2001) Idiopathic Type 1 diabetes. Journal of Diabetes and its Complications 15:6, 328-335
CrossRef85
Paul A. Dawson, Josyf C. Mychaleckyj, Sallyanne C. Fossey, S.John Mihic, Ann L. Craddock, Donald W. Bowden. (2001) Sequence and Functional Analysis of GLUT10: A Glucose Transporter in the Type 2 Diabetes-Linked Region of Chromosome 20q12–13.1. Molecular Genetics and Metabolism 74:1-2, 186-199
CrossRef86
Jason K. Kim, Yoon-Jung Kim, Jonathan J. Fillmore, Yan Chen, Irene Moore, Jongsoon Lee, Minsheng Yuan, Zhi Wei Li, Michael Karin, Pascale Perret, Steven E. Shoelson, Gerald I. Shulman. (2001) Prevention of fat-induced insulin resistance by salicylate. Journal of Clinical Investigation 108:3, 437-446
CrossRef87
Sallyanne C Fossey, Josyf C Mychaleckyj, Joanne K Pendleton, Jonathon R Snyder, Jeannette T Bensen, Shohei Hirakawa, Stephen S Rich, Barry I Freedman, Donald W Bowden. (2001) A High-Resolution 6.0-Megabase Transcript Map of the Type 2 Diabetes Susceptibility Region on Human Chromosome 20. Genomics 76:1-3, 45-57
CrossRef88
Lee Campbell, Mark Gumbleton, Kenneth Ritchie. (2001) Caveolae and the caveolins in human disease. Advanced Drug Delivery Reviews 49:3, 325-335
CrossRef89
Michael Roden. (2001) Non-invasive studies of glycogen metabolism in human skeletal muscle using nuclear magnetic resonance spectroscopy. Current Opinion in Clinical Nutrition and Metabolic Care 4:4, 261-266
CrossRef90
Jason K. Kim, Ariel Zisman, Jonathan J. Fillmore, Odile D. Peroni, Ko Kotani, Pascale Perret, Haihong Zong, Jianying Dong, C. Ronald Kahn, Barbara B. Kahn, Gerald I. Shulman. (2001) Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. Journal of Clinical Investigation 108:1, 153-160
CrossRef91
Cyrus Desouza, Lucía Gilling, Vivian Fonseca. (2001) Management of the insulin resistance syndrome. Current Diabetes Reports 1:2, 140-147
CrossRef92
Lester Packer, Klaus Krämer. 2001. R-_-Lipoic Acid. .
CrossRef93
Mike Mueckler. (2001) Insulin resistance and the disruption of Glut4 trafficking in skeletal muscle. Journal of Clinical Investigation 107:10, 1211-1213
CrossRef94
P. A. Scherpereel, B. Tavernier. (2001) Perioperative care of diabetic patients. European Journal of Anaesthesiology 18:5, 277-294
CrossRef95
Jun Nakae, Yoshiaki Kido, Tadahiro Kitamura, Domenico Accili. (2001) Glucose homeostasis: lessons from knockout mice. Current Opinion in Endocrinology & Diabetes 8:2, 82-87
CrossRef96
Chris Boesch, Roland Kreis. (2001) Dipolar coupling and ordering effects observed in magnetic resonance spectra of skeletal muscle. NMR in Biomedicine 14:2, 140-148
CrossRef97
Douglas L. Rothman. (2001) Studies of metabolic compartmentation and glucose transport usingin vivo MRS. NMR in Biomedicine 14:2, 149-160
CrossRef98
Robert G Shulman, Douglas L Rothman. (2001) 13 C NMR
OF INTERMEDIARY METABOLISM : Implications for Systemic Physiology. Annual Review of Physiology 63:1, 15-48
CrossRef99
H ZACUR. (2001) Polycystic Ovary Syndrome Hyperandrogenism, and Insulin Resistance. Obstetrics and Gynecology Clinics of North America 28:1, 21-33
CrossRef100
Makoto Hashimoto, Jing Yang, Geoffrey D. Holman. (2001) Cell-Surface Recognition of Biotinylated Membrane Proteins Requires Very Long Spacer Arms: An Example from Glucose-Transporter Probes. ChemBioChem 2:1, 52-59
CrossRef101
Bernhard R. Winkelmann, Georg Kneissl. (2001) Cigarette Smoking is Independently Associated with Markers of Endothelial Dysfunction and Hyperinsulinaemia in Non-diabetic Individuals with Coronary Artery Disease. Current Medical Research and Opinion 17:2, 132-141
CrossRef102
Elizabeth Murphy, Marc Hellerstein. (2000) Is In Vivo Nuclear Magnetic Resonance Spectroscopy Currently a Quantitative Method for Whole-body Carbohydrate Metabolism?. Nutrition Reviews 58:10, 304-314
CrossRef103
Werner K. Waldhäusl, Michael Roden. (2000) The effects of free fatty acids on glucose transport and phosphorylation in human skeletal muscle. Current Opinion in Endocrinology & Diabetes 7:4, 211-216
CrossRef104
Gerald I. Shulman. (2000) Cellular mechanisms of insulin resistance. Journal of Clinical Investigation 106:2, 171-176
CrossRef105
Jason K. Kim, M. Dodson Michael, Stephen F. Previs, Odile D. Peroni, Franck Mauvais-Jarvis, Susanne Neschen, Barbara B. Kahn, C. Ronald Kahn, Gerald I. Shulman. (2000) Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. Journal of Clinical Investigation 105:12, 1791-1797
CrossRef106
Konrad, Zeuzem, Vicini, Toffolo, Briem, Lormann, Herrmann, Berger, Kusterer, Teuber, Cobelli, Usadel. (2000) Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. European Journal of Clinical Investigation 30:2, 111-121
CrossRef107
Vincent Aguirre, Morris F. White. (2000) Dysregulation of IRS-proteins causes insulin resistance and diabetes. Current Opinion in Endocrinology & Diabetes 7:1, 1-7
CrossRef108
Matthew J. Brady, Alan R. Saltiel. (1999) Closing in on the cause of insulin resistance and type 2 diabetes. Journal of Clinical Investigation 104:6, 675-676
CrossRef109
Epstein, Franklin H., , Shepherd, Peter R., Kahn, Barbara B., . (1999) Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus. New England Journal of Medicine 341:4, 248-257
Full Text
